Cost-utility of a multicomponent intervention for fibromyalgia versus usual care : a pragmatic randomised controlled trial
OBJECTIVE: To perform an economic evaluation on a multicomponent intervention programme for patients with fibromyalgia syndrome compared with usual clinical practice in primary care.
DESIGN: A cost-utility analysis was conducted alongside a pragmatic randomised controlled trial (ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/record/NCT04049006) from a societal perspective, a human capital approach, and a 1-year time horizon.
PATIENTS: Patients diagnosed with fibromyalgia syndrome from the public health system in south Catalonia, Spain.
METHODS: Crude and adjusted incremental cost- utility ratios were estimated to compare the treatment strategies based on cost estimations (direct medical costs and productivity losses) and quality-adjusted life years. One-way and 2-way deterministic sensitivity analyses were performed.
RESULTS: The final analysed sample comprised 297 individuals, 161 in the intervention group and 136 in the control group. A crude incremental cost-utility ratio of € 1,780.75 and an adjusted ratio of € 851.67 were obtained, indicating that the programme significantly improved patients' quality of life with a cost-increasing outcome that fell below the cost-effectiveness threshold. The sensitivity analysis confirmed these findings when varying large cost components, and showed dominance when increasing session attendance.
CONCLUSION: The proposed multicomponent intervention programme was cost-effective compared with usual care for fibromyalgia, which supports its addition to standard practice in the regional primary care service.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Journal of rehabilitation medicine - 55(2023) vom: 19. Dez., Seite jrm12361 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arfuch, Victoria Mailen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 20.12.2023 Date Revised 30.12.2023 published: Electronic ClinicalTrials.gov: NCT04049006 Citation Status MEDLINE |
|---|
| doi: |
10.2340/jrm.v55.12361 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366026925 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366026925 | ||
| 003 | DE-627 | ||
| 005 | 20240108140239.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2340/jrm.v55.12361 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1243.xml |
| 035 | |a (DE-627)NLM366026925 | ||
| 035 | |a (NLM)38111994 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arfuch, Victoria Mailen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cost-utility of a multicomponent intervention for fibromyalgia versus usual care |b a pragmatic randomised controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.12.2023 | ||
| 500 | |a Date Revised 30.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04049006 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To perform an economic evaluation on a multicomponent intervention programme for patients with fibromyalgia syndrome compared with usual clinical practice in primary care | ||
| 520 | |a DESIGN: A cost-utility analysis was conducted alongside a pragmatic randomised controlled trial (ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/record/NCT04049006) from a societal perspective, a human capital approach, and a 1-year time horizon | ||
| 520 | |a PATIENTS: Patients diagnosed with fibromyalgia syndrome from the public health system in south Catalonia, Spain | ||
| 520 | |a METHODS: Crude and adjusted incremental cost- utility ratios were estimated to compare the treatment strategies based on cost estimations (direct medical costs and productivity losses) and quality-adjusted life years. One-way and 2-way deterministic sensitivity analyses were performed | ||
| 520 | |a RESULTS: The final analysed sample comprised 297 individuals, 161 in the intervention group and 136 in the control group. A crude incremental cost-utility ratio of € 1,780.75 and an adjusted ratio of € 851.67 were obtained, indicating that the programme significantly improved patients' quality of life with a cost-increasing outcome that fell below the cost-effectiveness threshold. The sensitivity analysis confirmed these findings when varying large cost components, and showed dominance when increasing session attendance | ||
| 520 | |a CONCLUSION: The proposed multicomponent intervention programme was cost-effective compared with usual care for fibromyalgia, which supports its addition to standard practice in the regional primary care service | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Pragmatic Clinical Trial | |
| 700 | 1 | |a Aguilar Martín, Carina |e verfasserin |4 aut | |
| 700 | 1 | |a Berenguera, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Caballol Angelats, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Gonçalves, Alessandra Queiroga |e verfasserin |4 aut | |
| 700 | 1 | |a Carrasco-Querol, Noèlia |e verfasserin |4 aut | |
| 700 | 1 | |a González Serra, Gemma |e verfasserin |4 aut | |
| 700 | 1 | |a Sancho Sol, Maria Cinta |e verfasserin |4 aut | |
| 700 | 1 | |a Fusté Anguera, Immaculada |e verfasserin |4 aut | |
| 700 | 1 | |a Friberg, Emilie |e verfasserin |4 aut | |
| 700 | 1 | |a Pettersson, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Casajuana, Marc |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of rehabilitation medicine |d 2001 |g 55(2023) vom: 19. Dez., Seite jrm12361 |w (DE-627)NLM113763042 |x 1651-2081 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2023 |g day:19 |g month:12 |g pages:jrm12361 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2340/jrm.v55.12361 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2023 |b 19 |c 12 |h jrm12361 | ||